A Phase 2 interventional study of Lifitegrast/Perfluorohexyloctane Fixed Dose Combination and Lifitegrast in Dry Eye Disease, sponsored by Bausch & Lomb Incorporated. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Bausch & Lomb Incorporated · Phase 2, Interventional, and Treatment
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.
This study's enrollment of 443 is above the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Bausch & Lomb Incorporated is the lead sponsor of 219 studies on the registry; 7 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 41 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
This study will include subjects who meet all of the following inclusion criteria:
Exclusion Criteria:
This study will exclude subjects who meet any of the following exclusion criteria (Note: Ocular exclusion criteria are relevant to both eyes, such that meeting a criterion in either eye excludes the subject from the study):
Additional criteria per protocol
Drug: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination
Drug: Lifitegrast
Drug: Perfluorohexyloctane
Drug: Vehicle
Drug: Vehicle
Drug: Vehicle
Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks
Topical ocular drop of lifitegrast administered for 4 weeks
Topical ocular drop of perfluorohexyloctane administered for 4 weeks
Topical ocular drop with no active ingredients administered for 4 weeks
Topical ocular drop with no active ingredients administered for 4 weeks
Topical ocular drop with no active ingredients administered for 4 weeks
Total corneal fluorescein staining change from baseline
Time frame: Baseline, day 29
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bausch & Lomb Incorporated